ERNA — Eterna Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $11.63m
- $12.04m
- $0.07m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K/A | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 19.8 | 5.8 | 0 | 0 | 0.068 |
Cost of Revenue | |||||
Gross Profit | 12.3 | 2.89 | — | — | -0.168 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 21.6 | 12.1 | 113 | 33.2 | 21.2 |
Operating Profit | -1.76 | -6.31 | -113 | -33.2 | -21.1 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.02 | -4.42 | -122 | -24.5 | -21.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.05 | -4.42 | -123 | -24.6 | -21.7 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.05 | -4.42 | -123 | -24.6 | -21.7 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.06 | -4.43 | -123 | -24.6 | -21.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -23.7 | -62.2 | -27.9 | -6.79 | -4.02 |